0000950170-24-026583.txt : 20240305 0000950170-24-026583.hdr.sgml : 20240305 20240305193823 ACCESSION NUMBER: 0000950170-24-026583 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sabens Andrea CENTRAL INDEX KEY: 0001876279 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 24723657 MAIL ADDRESS: STREET 1: C/O LANTHEUS HOLDINGS, INC. STREET 2: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 4 1 ownership.xml 4 X0508 4 2024-03-01 0001521036 Lantheus Holdings, Inc. LNTH 0001876279 Sabens Andrea C/O LANTHEUS HOLDINGS, INC. 201 BURLINGTON ROAD, SOUTH BLDG BEDFORD MA 01730 false true false false Chief Accounting Officer false Common Stock 2024-03-01 4 A false 5685 0.00 A 64088 D Common Stock 2024-03-04 4 A false 5817 0.00 A 69905 D Stock Option (right to buy) 64.64 2024-03-01 4 A false 3368 0.00 A 2034-03-01 Common Stock 3368 3368 D Consists of 1,895 restricted stock units that vest in equal installments over a three-year period and 3,790 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. The transaction reported in this Form 4 reflects additional shares of common stock issued by the Company to the reporting person upon the vesting of relative Total Shareholder Return PSUs that were previously granted and included in the Form 3 filed upon the reporting person becoming a Section 16 officer. The number of shares reported in the Form 3 reflected 100% of the target number of shares underlying the PSUs. The number of shares that actually vested under the PSUs equaled 200% of the target number of shares. Accordingly, the number of shares reported in this Form 4 reflects the difference between the number of shares that actually vested under the PSUs and the target number of shares originally included in the Form 3. The option vests in three equal annual installments beginning on March 1, 2025. /s/ Eric M. Green, attorney-in-fact 2024-03-05